About US
Contact us
>>Back
Avantor and Rubicon to collaborate on novel gastro-retentive excipient
- Publisher：
- Publication：2012/10/19
Avantor Performance Materials has signed a collaborative agreement with Rubicon Research which should lead to the development of a new gastro-retentive excipient.
Mumbai-based Rubicon is recognised as a leader in the field of drug delivery technology, providing solutions for gastric retention, bioavailability enhancement and taste masking.
Its proprietary product technology will be combined with Avantor's manufacturing and marketing expertise to develop a novel gastro-retentive excipient that enables the delivery of molecules having a window of absorption.
Paul Smaltz, executive vice president of pharmaceuticals and the Americas for Avantor, said he was "delighted" to be working with Rubicon to develop and market a product with significant therapeutic advantage.
"The combination of Rubicon's groundbreaking technology and our strong position in the global marketplace for functional excipients will result in outstanding products to help our pharmaceutical customers in their pursuit of patient dosage compliance, and safety," he claimed.
It is hoped that the first excipients resulting from the partnership will be launched in 2013.